Recent Press Releases

Alvogen Launches the First Generic Exelon® Patch in the United States

September 04, 2015 08:57 AM Eastern Daylight Time PINE BROOK, N.J.--()--Today, Alvogen has launched the first generic equivalent of Exelon® patch (rivastigmine transdermal...

Surefire Medical Receives FDA Clearance for Precision Direct-to-Tumor Embolization Device

WESTMINSTER, Colo.--(BUSINESS WIRE)--Surefire Medical, Inc., developer of a new class of direct-to-tumor treatment delivery devices employed in minimally invasive chemoembolization and...

Teva Announces U.S. Availability of ZECUITY® (sumatriptan iontophoretic transdermal system), First and Only Transdermal Patch System for the Acute Treatment of Migraine

September 01, 2015 08:00 AM Eastern Daylight Time JERUSALEM--()--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that ZECUITY®, the first and only patch system...

TITAN PHARMACEUTICALS ANNOUNCES RESUBMISSION OF THE NEW DRUG APPLICATION FOR PROBUPHINE FOR THE MAINTENANCE TREATMENT OF OPIOID ADDICTION

SOUTH SAN FRANCISCO, CA – August 31, 2014 – Titan Pharmaceuticals, Inc.(OTCQB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select...

Nuvo Research granted U.S. patent for novel topical foam formulations that use DMSO to enhance drug delivery

Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced that the United States Patent Office has granted U.S....

Highland Therapeutics Announces Initiation of Second Pivotal Trial of HLD-200 in Pediatric ADHD Patients

August 24, 2015 11:45 AM Eastern Daylight Time The AHEAD study will focus on the Early Morning Routine (EMR) TORONTO--()--Highland Therapeutics Inc. ("Highland") announced...

Matinas BioPharma's Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations by U.S. FDA

Matinas BioPharma's Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations by U.S. FDA BEDMINSTER, N.J., Aug. 18, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings,...

Former Employee Issues Apology and Withdraws Whistleblower Lawsuit

YORK, Pa., Aug. 19, 2015 /PRNewswire/ -- Unilife Corporation , a developer, manufacturer and supplier of injectable drug delivery systems, today announced that a former employee has agreed to dismiss...

Orexo: U.S. FDA Approves ZUBSOLV® for Induction of Buprenorphine Maintenance Therapy in Patients Suffering from Opioid Dependence

CHARLOTTE, N.C., Aug. 13, 2015 /PRNewswire/ -- FSC Pediatrics announced today the launch of Karbinal™ ER, the only 1st generation extended-release oral suspension antihistamine available in the...

Orexo: U.S. FDA Approves ZUBSOLV® for Induction of Buprenorphine Maintenance Therapy in Patients Suffering from Opioid Dependence

August 11, 2015 02:39 AM Eastern Daylight Time UPPSALA, Sweden--()--Regulatory News: Orexo AB (publ) announced today that the U.S. Food and Drug Administration (FDA) has approved...

FSC Pediatrics Launches Karbinal™ ER (Carbinoxamine Maleate) for the Symptomatic Treatment of Seasonal and Perennial Allergic Rhinitis for Children

FSC Pediatrics announced today the launch of Karbinal™ ER, the only 1st generation extended-release oral suspension antihistamine available in the U.S. Karbinal ER is an H1 receptor antagonist...

FSC Pediatrics Launches Karbinal™ ER (Carbinoxamine Maleate) for the Symptomatic Treatment of Seasonal and Perennial Allergic Rhinitis for Children

FSC Pediatrics announced today the launch of Karbinal™ ER, the only 1st generation extended-release oral suspension antihistamine available in the U.S. Karbinal ER is an H1 receptor antagonist...

Protein-Engineered Gels Mimic Body's Own Functions

U.S. Army Research Office Backs NYU Engineering Team's Investigation of Hydrogels that Could Heal Wounds or Stick like Spiderman BROOKLYN, N.Y., Aug. 10, 2015 /PRNewswire-USNewswire/ -- The U.S....

Checkmate Pharmaceuticals Debuts with $20 Million Series A Investment for Development of Novel Immuno-Oncology Product Platform

August 12, 2015 01:00 AM Eastern Daylight Time CAMBRIDGE, Mass.--()--Checkmate Pharmaceuticals, a biopharmaceutical company focused on developing novel approaches for cancer...

Checkmate Pharmaceuticals Debuts with $20 Million Series A Investment for Development of Novel Immuno-Oncology Product Platform

CAMBRIDGE, Mass.--()--Checkmate Pharmaceuticals, a biopharmaceutical company focused on developing novel approaches for cancer immunotherapy, announced today their $20 million Series A...

BioDelivery Sciences Announces FDA Approval of New Formulation of ONSOLIS® (fentanyl buccal soluble film) CII

Approval of new formulation expected to allow ONSOLIS to return to U.S. market in 2016 RALEIGH, N.C., Aug. 13, 2015 -- BioDelivery Sciences International, Inc. (BDSI) announced the approval by the...

BioDelivery Sciences Announces FDA Approval of New Formulation of ONSOLIS® (fentanyl buccal soluble film) CII

Approval of new formulation expected to allow ONSOLIS to return to U.S. market in 2016 RALEIGH, N.C., Aug. 13, 2015 -- BioDelivery Sciences International, Inc. (BDSI) announced the approval by the...

MonoSol Rx Partner Galena Biopharma Launches Zuplenz(R) (Ondanestron) Oral Soluble Film

MonoSol Rx, a specialty pharmaceutical company leveraging its PharmFilm® drug delivery technology to develop treatments that improve patient outcomes and address unmet needs, announced that its...

CTX Acquires Promising Proprietary Drug Delivery Assets

August 04, 2015 12:21 PM Eastern Daylight Time TUCSON, Ariz.--()--CTX Technology Inc., based in Tucson, Arizona, has acquired the intellectual property, formulations and related...

Cipher Pharmaceuticals announces acceptance of 510(k) submission for Dermadexin™ by FDA

- Acceptance marks first regulatory filing with FDA since Absorica® in 2011 - MISSISSAUGA, ON, Aug. 4, 2015 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ: CPHR; TSX:CPH) ("Cipher"...